ArticleThe American journal of case reports2026
A 56-Year-Old Woman With Systemic Lupus Erythematosus on Trimethoprim-Sulfamethoxazole Prophylaxis Presenting With Breakthrough Nocardiosis.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Patients with primary or secondary immunosuppression can be treated with trimethoprim-sulfamethoxazole (TMP-SMX) as long-term prophylaxis to prevent opportunistic infections. Nocardia africana/nova is an aerobic, gram-positive opportunistic organism. This case report describes a patient with systemic lupus erythematosus (SLE) on low-dose TMP-SMX prophylaxis who developed nocardiosis due to N. africana/nova. CASE REPORT A 56-year-old Chinese woman with SLE on long-term low-dose TMP-SMX prophylaxis underwent partial right lung lobectomy in July 2023 after incidental pulmonary lesions were detected. Pathology revealed a cryptococcal granuloma, which was treated with fluconazole. In November 2024, chest computed tomography (CT) showed progressive pulmonary nodules and right upper lobe consolidation despite antibacterial and antifungal therapy, including voriconazole guided by next-generation sequencing. CT-guided lung biopsy confirmed pulmonary nocardiosis caused by N. africana/nova, susceptible in vitro to TMP-SMX. High-dose TMP-SMX plus linezolid led to radiologic improvement, after which TMP-SMX monotherapy was continued. In March 2025, she was readmitted with acute altered mental status, recurrent cavitary pulmonary disease, pleural effusion, and multiple ring-enhancing cerebral abscesses, consistent with disseminated nocardiosis. Further aggressive treatment was declined, and she was discharged for palliative care. CONCLUSIONS Nocardiosis is challenging to diagnose and treat in immunocompromised patients, as breakthrough infections can occur despite in vitro susceptibility, reflecting the roles of host immunity and drug factors. Clinicians should maintain a high index of suspicion for nocardiosis in patients receiving corticosteroids or other immunosuppressive therapies and recognize that in vitro susceptibility does not always predict in vivo therapeutic success. This report highlights that breakthrough nocardia can occur with appropriate low-dose TMP-SMX prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.